购物车
- 全部删除
- 您的购物车当前为空
Zibotentan (ZD4054) 是一种选择性的,具有口服活性的内皮素 A (ETA) 受体拮抗剂,Ki 为 13 nM。它具有抗癌作用,可研究去势抵抗性前列腺癌。
为众多的药物研发团队赋能,
让新药发现更简单!
Zibotentan (ZD4054) 是一种选择性的,具有口服活性的内皮素 A (ETA) 受体拮抗剂,Ki 为 13 nM。它具有抗癌作用,可研究去势抵抗性前列腺癌。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 385 | 现货 | |
2 mg | ¥ 549 | 现货 | |
5 mg | ¥ 872 | 现货 | |
10 mg | ¥ 1,490 | 现货 | |
25 mg | ¥ 2,530 | 现货 | |
50 mg | 询价 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 959 | 现货 |
产品描述 | Zibotentan (ZD4054) (ZD4054) is a specific Endothelin (ET)A antagonist with IC50 of 21 nM, exhibiting no activity at ETB. Phase 3. |
靶点活性 | ETA:21 nM |
体外活性 | Zibotentan专门抑制ETA介导的抗凋亡效应,而不影响ETB介导的促凋亡效应,在人类和大鼠的平滑肌细胞中,Zibotentan高亲和力地结合于内皮素A受体(ETA),Ki值为13 nM,对内皮素B受体(ETB)无亲和力,IC50值>10 μM。[1] 1 μM的Zibotentan处理抑制在分泌ET-1且表达ETA和ETB mRNA的卵巢癌细胞系HEY和OVCA 433中ET-1诱导的有丝分裂活性。[2] ZD4054(1 μM)抑制ET-1在HEY和OVCA 433细胞中诱导的EGFR转激活。Zibotentan(1 μM)通过增强E-钙黏蛋白表达和启动子活性,以及抑制血管内皮生长因子(VEGF)分泌和侵袭性,逆转ET-1介导的上皮-间质转换(EMT)。[3] Zibotentan还强效地抑制在SKOV-3和A-2780细胞中基础和ET-1诱导的细胞增殖,这与AKT和p42/44MAPK磷酸化的抑制、bcl-2的抑制和caspase-3及多聚(ADP-核糖)聚合酶蛋白的激活增加的凋亡有关。[4] |
体内活性 | 给予小鼠Zibotentan 10 mg/kg/日,连续21天的处理显著抑制HEY卵巢癌异种移植瘤的增长,抑制率达69%,且未观察到相关毒性。这与通过Ki-67表达的37%抑制评估的细胞增殖阻断,以及62%的肿瘤诱导血管生成抑制有关。一致地,Zibotentan处理显著抑制基质金属蛋白酶-2(MMP-2)和VEGF的表达,以及p42/44 MAPK和EGFR的激活,并强力增强E-cadherin的表达。[3] |
激酶实验 | Receptor-binding assays: The inhibition by Zibotentan (varying concentrations) of 125iodine-ET-1 binding to cloned human ETA is assessed using standard radioligand-binding techniques. Human recombinant ETA is expressed in mouse erythroleukaemic cells, and cell membranes prepared for competitive binding studies using 125iodine-ET-1 as the radioligand. Incubations are carried out in triplicate in the presence of Zibotentan, 100 pM to 100 μM in half-log increments, and inhibition of ET-1 binding is expressed as the geometric mean pIC50 value (concentration to inhibit 50% of binding) with a 95% confidence interval (CI). The affinity of Zibotentan for cloned human ETA is also assessed using the equation of Cheng and Prusoff to determine the equilibrium dissociation constant (Ki) in a further receptor-binding screen utilizing a greater number of concentration-response curves determined in three separate studies. |
细胞实验 | Cells are serum starved by incubation for 24 hours in serum-free DMEM before exposed to Zibotentan for 48 hours. After the treatment, cells are lysed and the supernatant is recovered and assayed for histone-associated DNA fragments, at 405 nm by the use of a microplate reader. For detection of early apoptotic events, floating and adherent cells are collected. Cells are double stained with FITC-conjugated Annexin V and propidium iodide using the Vybrant Apoptosis Kit and are immediately analyzed by cytofluorometric analysis.(Only for Reference) |
别名 | ZD4054 |
分子量 | 424.43 |
分子式 | C19H16N6O4S |
CAS No. | 186497-07-4 |
Smiles | COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1 |
密度 | 1.422 g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 23 mg/mL (54.2 mM) Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容